NASDAQ: SKYASkyai Inc Stock
$1.25+0.13 (+11.61%)
Updated Jun 15, 2026
SKYA Price
$1.25
Fair Value Price
N/A
Market Cap
$52.90M
52 Week Low
$1.02
52 Week High
$18.23
P/E
-0.95x
P/B
0.3x
P/S
11.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.34M
Earnings
-$370.67M
Gross Margin
92.1%
Operating Margin
-3,588.33%
Profit Margin
-3,586.2%
Debt to Equity
0.01
Operating Cash Flow
-$11M
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SKYA Overview
Sharps Technology Incorporated is a medical device company that manufactures and sells safety syringe products in the U.S. Its 'Sharps Provensa' offering is a smart safety syringe designed to eliminate potentially infectious accidental needlestick injuries Sharps Technology was incorporated in 2017 and is headquartered in Melville, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SKYA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Software Infrastructure
Industry Rating
C
SKYA
Ranked#110 of 130
Ranked#110 of 130
Be the first to know about important SKYA news, forecast changes, insider trades & much more!
SKYA News
Overview
Due Diligence Score
–
Industry Average (33)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SKYA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SKYA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SKYA is good value based on its book value relative to its share price (0.3x), compared to the US Software - Infrastructure industry average (7.93x)
P/B vs Industry Valuation
SKYA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SKYA due diligence checks available for Premium users.
Valuation
SKYA fair value
Fair Value of SKYA stock based on Discounted Cash Flow (DCF)
Price
$1.25
Fair Value
$0.33
Overvalued by
281.86%
SKYA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SKYA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.95x
Industry
-213.23x
Market
14.3x
SKYA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.3x
Industry
7.93x
SKYA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SKYA's financial health
Profit margin
Revenue
$3.3M
Net Income
-$86.2M
Profit Margin
-2,592.2%
SKYA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SKYA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$181.0M
Liabilities
$2.2M
Debt to equity
0.01
SKYA's short-term assets ($18.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SKYA's short-term assets ($18.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SKYA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
$9.3M
Financing
-$4.7M
SKYA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SKYA vs Software Infrastructure Stocks
Skyai Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.